Vaccine prevention of meningococcal disease: Making slow progress

Clinical Infectious Diseases

Volumn 43, Issue 11, 2006, Pages 1395-1397

  Harrison, Lee H ^a,b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ADOLESCENT; ADOLESCENT DISEASE; ANTIBODY TITER; CHILD; CHILD HEALTH CARE; CHILDHOOD DISEASE; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFANT; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; NOTE; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINATION; VACCINE PRODUCTION;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; WORLD HEALTH;

EID: 33751581521     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/508780     Document Type: Note

References (18)

1. Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 2006; 19:142-64.
2. Harrison LH. The worldwide prevention of meningococcal infection: still an elusive goal. JAMA 1995; 273:419-21.
3. Soriano-Gabarro M, Rosenstein N, LaForce FM. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project. J Health Popul Nutr 2004; 22:275-85.
4. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005; 23:2191-6.
5. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006; 103:10834-9.
6. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54:1-21.
7. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20(Suppl 1):S58-67.
8. Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal semigroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357:195-6.
9. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003; 326:365-6.
10. Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 359:1829-31.
11. Richmond P, Borrow R, Miller E, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999; 179:1569-72.
12. Borrow R, Goldblatt D, Finn A, et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. Infect Immun 2003; 71:5549-55.
13. MacLennan JM, Shackley F, Heath PT, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 2000; 283: 2795-801.
14. Leach A, Twumasi PA, Kumah S, et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 1997; 175:200-4.
15. Borrow R, Goldblatt D, Andrews N, et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom. J Infect Dis 2002; 186:1353-7.
16. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-7.
17. Snape MD, Kelly DF, Salt P, et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 2006; 43:1387-94 (in this issue).
18. Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998; 178:870-4.